瑞舒伐他汀钙对高血压患者颈动脉内膜中层厚度及血清高敏C反应蛋白影响的研究

目的观察高血压人群中，在常规降压治疗的同时联用他汀类药物，通过对血脂指标、hs—CRP、颈动脉内膜中层厚度（IMT）及斑块的的检测，探讨他汀类药物及早应用能否更好的控制动脉粥样硬化的进展。方法选取高血压的患者405例，分为对照组（202例），研究组（203例）均接受降压药物治疗，研究组同时予以瑞舒伐他汀钙10mg／日，研究周期为18个月，检测基线、6月、12月、嘏月时高敏c反应蛋白（hsCRP）、血脂系列；同时检查基线及18个月颈动脉内膜中层厚度（IMT）及颈动脉斑块。结果他汀组TC、TG、LDL—C、hsCRP在6、12、18个月检测指标均有下降，组内、组间比较（P〈0．05），HDL—C较对照组及基线均有升高（P〈0．05），差异有统计学意义，18个月IMT及斑块检出率较对照组及基线均有统计学差异（P〈0.05）。结论瑞舒伐他汀钙具有良好的调脂、抗炎和抗颈动脉粥样硬化作用。

The Effects of Rosuvastatin on Carotid Atherosclerosis and Serum High-sensitive C-reaction Protein in Hypertension

Objective The aim of this prospective case-series study was to determine whether rosuvastatin is effective ha decreasing serum levels of inflammatory biomarkers and slowing progression of carotid atherosclerosis in patients with hypertension. Methods 405 patients with hypertension were randomly assigned to the control group （n=203） or the rosuvastatin （20 mg once daily） group （n=202） during a 18-month treatment period. Carotid intima media thickness （1MT）, lipid profile and high-sensitive C-reaction protein（hs-CRP） were assessed after 6, 12 months and at the end of the study （18 months）. Results Total cholesterol, low-density lipoprotein cholesterol, triglycerides and hs-CRP decreased significantly （p〈0.05） in the rosuvastatin treatment group, while high-density lipoprotein cholesterol increased significantly （P〈0.05） during the intervention, compared with the control group and baseline. At 18 months, the IMT of the internal carotid arteries appeared to be decreased in patients treated with rosuvastatin （p〈0.05）. Conclusion 18-month treatment with rosuvastatin in hypertensive adults significantly reduced the IMT and improved the lipid and inflammatory biomarker levels.